DAM-57
From Wikipedia, the free encyclopedia
 |
|
|
DAM-57
|
|
| Systematic (IUPAC) name | |
| (6aR,9R)-N,N-dimethyl-7-methyl-4,6,6a,7,8,9- hexahydroindolo-[4,3-fg]quinoline-9-carboxamide |
|
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | C18H21N3O |
| Mol. mass | 295.39 g/mol |
| Synonyms | DAM-57, Lysergic acid dimethylamide |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | hepatic |
| Half life | ? |
| Excretion | renal |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
Controlled in the US via the Federal Analog Act |
| Routes | Oral |
N,N-Dimethyllysergamide (DAM-57) is a derivative of ergine.
It may cause LSD-like effects at doses of 1 milligram or more but this is disputed.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||
